Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01624285 · ClinicalTrials.gov registry record · Phase 2
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01624285 is a Phase 2 study that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 20 participants.
The verdict
NCT01624285, a Phase 2 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation. Liver transplantation is a treatment option for liver cancer patients, but despite transplantation, the liver cancer can recur in the new, transplanted liver. It is not known whether sorafenib is effective in preventing cancer recurrence in high risk patients following liver transplantation
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- DRUG sorafenib tosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-07-16 |
| Est. Completion | 2023-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01624285
The ClinicalTrials.gov registry entry for NCT01624285 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01624285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01624285 about?
NCT01624285 is a clinical study titled "Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer". The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation. Liver transplantation is a treatment option for liver cancer patients, but despite transplantation, ...
What is the current status of trial NCT01624285?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2012-07-16. Estimated completion is 2023-02.
What interventions are being tested in trial NCT01624285?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT01624285?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.